Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs

BOSTON and LONDON, July 25, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (R&D) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced the appointment of Harris L. Rotman, PhD, as Senior Vice President, Regulatory Affairs.

“We are very pleased to welcome Harris to our leadership team as we prepare for our SerpinPC program in Hemophilia B to move into registrational studies this year and continue to steadily advance our innovative rare disease and immuno-oncology pipeline,” said Saurabh Saha, MD, PhD, Chief Executive Officer of Centessa.

“I’m thrilled to join the impressive team at Centessa,” said Dr. Rotman. “This is a rare opportunity to join a company where each program has the benefit of extraordinary R&D talent and deep industry experience. I look forward to helping advance Centessa’s compelling pipeline for patients with unmet needs.”

Prior to joining Centessa, Dr. Rotman served as Senior Vice President, Head of Regulatory Affairs at SwanBio Therapeutics, where he was responsible for managing the company’s neuromuscular disease gene therapy programs. Dr. Rotman also previously served as Vice President, Head of Regulatory Affairs, Branded Business at Endo Pharmaceuticals where he led the branded global regulatory affairs department in the US and Ireland. Earlier in his career, Dr. Rotman held executive regulatory leadership roles with Indivior, Shire Pharmaceuticals, Sanofi and Wyeth Pharmaceuticals. Dr. Rotman earned his PhD in Microbiology and Molecular Virology from Thomas Jefferson University, and a BS in Biological Sciences from Cook College at Rutgers University.

About Centessa Pharmaceuticals

is a clinical-stage pharmaceutical company with an R&D innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients. Our programs span discovery-stage to late-stage development and cover a range of high-value indications in rare diseases and immuno-oncology. We are led by a management team with extensive R&D experience, providing direct guidance to our program teams to rapidly advance our candidates from research through all stages of development. For more information, visit , which does not form part of this release.

Forward Looking Statements

This press release contains forward-looking statements. These statements may be identified by words such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” “aim,” “seek,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including statements regarding the expected benefits of Dr. Rotman’s employment; statements concerning the prospects of our programs; statements related to the Company’s ability to develop our programs (including our SerpinPC program) and deliver impactful medicines to patients; the ability of our key executives to drive execution of the Company’s portfolio of programs; our asset-centric business model and the intended advantages and benefits thereof; and research and clinical development plans and the timing thereof. Any forward-looking statements in this press release are based on our current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the safety and tolerability profile of our product candidates; our ability to protect and maintain our intellectual property position; business (including commercial viability), regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about the Company; risks inherent in developing products and technologies; future results from our ongoing and planned clinical trials; our ability to obtain adequate financing, including through our financing facility with Oberland, to fund our planned clinical trials and other expenses; trends in the industry; the legal and regulatory framework for the industry, including the receipt and maintenance of clearances to conduct or continue clinical testing; future expenditures risks related to our asset-centric corporate model; the risk that any one or more of our product candidates will not be successfully developed and/or commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; geo-political risks such as the Russia-Ukraine war and risks related to the ongoing COVID-19 pandemic including the effects of the Delta, Omicron and any other variants. These and other risks concerning our programs and operations are described in additional detail in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, and our other reports, which are on file with the U.S. Securities and Exchange Commission. We explicitly disclaim any obligation to update any forward-looking statements except to the extent required by law.

Contact:

Kristen K. Sheppard, Esq.

SVP of Investor Relations